Alaunos Therapeutics Inc (TCRT) - Net Assets
Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) has net assets worth $2.15 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.97 Million) and total liabilities ($813.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Alaunos Therapeutics Inc (TCRT) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.15 Million |
| % of Total Assets | 72.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | -96.29% |
| 10-Year Change | N/A |
| Growth Volatility | 122.02 |
Alaunos Therapeutics Inc - Net Assets Trend (2001–2025)
This chart illustrates how Alaunos Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Alaunos Therapeutics Inc for the complete picture of this company's asset base.
Annual Net Assets for Alaunos Therapeutics Inc (2001–2025)
The table below shows the annual net assets of Alaunos Therapeutics Inc from 2001 to 2025. For live valuation and market cap data, see Alaunos Therapeutics Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.15 Million | +4.36% |
| 2024-12-31 | $2.06 Million | -67.29% |
| 2023-12-31 | $6.31 Million | -83.64% |
| 2022-12-31 | $38.55 Million | -33.59% |
| 2021-12-31 | $58.06 Million | -53.17% |
| 2020-12-31 | $123.98 Million | +30.49% |
| 2019-12-31 | $95.01 Million | +11.04% |
| 2018-12-31 | $85.56 Million | +188.39% |
| 2017-12-31 | $-96.81 Million | -25.24% |
| 2016-12-31 | $-77.30 Million | -188.47% |
| 2015-12-31 | $87.37 Million | +158.18% |
| 2014-12-31 | $33.84 Million | -31.47% |
| 2013-12-31 | $49.38 Million | +1.94% |
| 2012-12-31 | $48.45 Million | -32.35% |
| 2011-12-31 | $71.61 Million | +134.37% |
| 2010-12-31 | $30.55 Million | +8.71% |
| 2009-12-31 | $28.10 Million | +317.04% |
| 2008-12-31 | $6.74 Million | -77.81% |
| 2007-12-31 | $30.37 Million | +14.46% |
| 2006-12-31 | $26.53 Million | +268.42% |
| 2005-12-31 | $7.20 Million | +34354.11% |
| 2004-12-31 | $-21.02K | +18.15% |
| 2003-12-31 | $-25.69K | -48.18% |
| 2002-12-31 | $-17.33K | -562.87% |
| 2001-12-31 | $-2.62K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alaunos Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 92445146600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.09% |
| Other Components | $926.77 Million | 43045.66% |
| Total Equity | $2.15 Million | 100.00% |
Alaunos Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Alaunos Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Betacom S.A.
WAR:BCM
|
$5.83 Million |
|
Gayatri Highways Limited
NSE:GAYAHWS
|
$5.83 Million |
|
Warehouse REIT plc
LSE:WHR
|
$5.84 Million |
|
Munic SA
PA:ALMUN
|
$5.84 Million |
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
$5.82 Million |
|
Gentrogroup Co. Ltd.
KQ:083660
|
$5.82 Million |
|
CHINA HEALTH GRP HD-10
F:VNL1
|
$5.82 Million |
|
mTouche Technology Bhd
KLSE:0092
|
$5.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alaunos Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,063,000 to 2,153,000, a change of 90,000 (4.4%).
- Net loss of 4,176,000 reduced equity.
- New share issuances of 3,261,000 increased equity.
- Other factors increased equity by 1,005,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.18 Million | -193.96% |
| Share Issuances | $3.26 Million | +151.46% |
| Other Changes | $1.00 Million | +46.68% |
| Total Change | $- | 4.36% |
Book Value vs Market Value Analysis
This analysis compares Alaunos Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $-9.33 | $2.61 | x |
| 2002-12-31 | $-11.60 | $2.61 | x |
| 2003-12-31 | $-13.12 | $2.61 | x |
| 2004-12-31 | $-21.17 | $2.61 | x |
| 2005-12-31 | $198.90 | $2.61 | x |
| 2006-12-31 | $316.57 | $2.61 | x |
| 2007-12-31 | $241.90 | $2.61 | x |
| 2008-12-31 | $47.61 | $2.61 | x |
| 2009-12-31 | $182.43 | $2.61 | x |
| 2010-12-31 | $99.62 | $2.61 | x |
| 2011-12-31 | $162.73 | $2.61 | x |
| 2012-12-31 | $92.52 | $2.61 | x |
| 2013-12-31 | $86.19 | $2.61 | x |
| 2014-12-31 | $50.19 | $2.61 | x |
| 2015-12-31 | $104.50 | $2.61 | x |
| 2016-12-31 | $-88.92 | $2.61 | x |
| 2017-12-31 | $-106.04 | $2.61 | x |
| 2018-12-31 | $89.43 | $2.61 | x |
| 2019-12-31 | $84.85 | $2.61 | x |
| 2020-12-31 | $88.71 | $2.61 | x |
| 2021-12-31 | $40.62 | $2.61 | x |
| 2022-12-31 | $26.63 | $2.61 | x |
| 2023-12-31 | $3.94 | $2.61 | x |
| 2024-12-31 | $1.29 | $2.61 | x |
| 2025-12-31 | $1.11 | $2.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alaunos Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -193.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -83520.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.38x
- Recent ROE (-193.96%) is below the historical average (-115.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 0.00% | -4202.49% | 0.60x | 0.00x | $-71.14K |
| 2002 | 0.00% | -1554.12% | 5.13x | 0.00x | $-38.21K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-33.27K |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-37.06K |
| 2005 | -132.14% | 0.00% | 0.00x | 1.32x | $-10.24 Million |
| 2006 | -67.30% | 0.00% | 0.00x | 1.11x | $-20.51 Million |
| 2007 | -87.61% | 0.00% | 0.00x | 1.21x | $-29.65 Million |
| 2008 | -374.40% | 0.00% | 0.00x | 1.87x | $-25.90 Million |
| 2009 | -27.22% | 0.00% | 0.00x | 1.77x | $-10.46 Million |
| 2010 | -106.93% | 0.00% | 0.00x | 2.01x | $-35.73 Million |
| 2011 | -89.07% | -9561.92% | 0.01x | 1.51x | $-70.94 Million |
| 2012 | -198.44% | -12016.50% | 0.01x | 1.72x | $-100.98 Million |
| 2013 | -115.64% | -7138.38% | 0.01x | 1.45x | $-62.05 Million |
| 2014 | -93.91% | -2314.71% | 0.03x | 1.34x | $-35.17 Million |
| 2015 | -137.45% | -2772.11% | 0.03x | 1.76x | $-128.83 Million |
| 2016 | 0.00% | -2409.23% | 0.06x | 0.00x | $-157.57 Million |
| 2017 | 0.00% | -850.26% | 0.06x | 0.00x | $-44.64 Million |
| 2018 | -62.08% | -36381.51% | 0.00x | 1.11x | $-61.67 Million |
| 2019 | -123.98% | 0.00% | 0.00x | 1.15x | $-127.30 Million |
| 2020 | -63.60% | 0.00% | 0.00x | 1.18x | $-91.25 Million |
| 2021 | -135.64% | -19786.68% | 0.00x | 1.63x | $-84.56 Million |
| 2022 | -97.86% | -1291.24% | 0.04x | 1.68x | $-41.59 Million |
| 2023 | -557.16% | -702800.00% | 0.00x | 1.31x | $-35.77 Million |
| 2024 | -226.81% | -46790.00% | 0.00x | 1.34x | $-4.89 Million |
| 2025 | -193.96% | -83520.00% | 0.00x | 1.38x | $-4.39 Million |
Industry Comparison
This section compares Alaunos Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alaunos Therapeutics Inc (TCRT) | $2.15 Million | 0.00% | 0.38x | $5.83 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression.… Read more